| Pulmonary arterial hypertension
Tyvaso vs Uptravi
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Tyvaso vs Uptravi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUptravi has a higher rate of injection site reactions vs Tyvaso based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uptravi but not Tyvaso, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tyvaso
Uptravi
At A Glance
Oral inhalation
4 times daily
Prostacyclin analogue
Oral / IV infusion
Twice daily
Prostacyclin receptor agonist
Indications
- Pulmonary arterial hypertension
- Pulmonary hypertension due to interstitial lung disease
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension, Pulmonary hypertension due to interstitial lung disease Initial dose: 3 breaths (18 mcg) per treatment session 4 times daily via the Tyvaso Inhalation System; if not tolerated, reduce to 1-2 breaths. Increase by 3 breaths per session every 1-2 weeks as tolerated to target maintenance dose of 9-12 breaths per session 4 times daily.
Pulmonary arterial hypertension Starting dose 200 mcg orally twice daily; increase by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily. For moderate hepatic impairment (Child-Pugh class B), start at 200 mcg once daily and increase by 200 mcg once daily at weekly intervals. When co-administered with a moderate CYP2C8 inhibitor, reduce dosing to once daily. IV infusion (80-minute) is dosed twice daily at the corresponding tablet dose for patients temporarily unable to take oral therapy.
Contraindications
—
- Hypersensitivity to selexipag or any excipient
- Concomitant use of strong CYP2C8 inhibitors (e.g., gemfibrozil)
Adverse Reactions
Most common (>=4%) Cough, headache, throat irritation/pharyngolaryngeal pain, nausea, flushing, syncope
Serious Decrease in systemic blood pressure, bleeding
Postmarketing Angioedema
Most common (>=3%) Headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in extremity, flushing, arthralgia, rash, anemia, decreased appetite
Postmarketing Symptomatic hypotension
Pharmacology
Treprostinil is a prostacyclin analogue whose major pharmacologic actions are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.
Selexipag is a prostacyclin receptor (IP receptor) agonist structurally distinct from prostacyclin; it is hydrolyzed by carboxylesterase 1 to an active metabolite approximately 37-fold more potent, selective for the IP receptor over other prostanoid receptors (EP1-4, DP, FP, and TP).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tyvaso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Uptravi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Tyvaso
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Uptravi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Tyvaso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Uptravi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Janssen CarePath Oral PAH Savings Program: UptraviCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TyvasoView full Tyvaso profile
UptraviView full Uptravi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.